FDA Grants Priority Review to Rituximab for Children with 2 Rare Forms of Vasculitis

Officials with the FDA granted Priority Review to Genentech’s supplemental Biologics License Application (sBLA) for rituximab (Rituxan) in combination with glucocorticoids (GCCs) for the treatment of 2 rare forms of vasculitis in pediatric patients, according to a press release.
 
If approved, rituximab plus GCCs would be indicated for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older. Currently, rituximab plus GCCs is the only FDA-approved therapy for the treatment of adults with these 2 conditions and approval of the sBLA would represent the first pediatric indication for rituximab.
 
GPA and MPA are rare, potentially life-threatening diseases that affect small- and medium-sized blood vessels, primarily in the kidneys, lungs, sinuses, and a variety of other organs. Cases of pediatric onset of these conditions are even more rare and can result in severe, life-threatening symptoms, according to Genentech.
 
The sBLA submission was based on data from the phase 2a PePRS study evaluating the safety, pharmacodynamics/pharmacokinetics, and exploratory efficacy of intravenous rituximab. The trial included 25 patients with severe GPA or MPA between 6 and 17 years old. In the study, pediatric patients with newly-diagnosed or relapsing active GPA or MPA were treated with 4 weekly infusions of rituximab in combination with a tapering course of oral GCCs. The results demonstrated no new safety signals with rituximab treatment.
 
All 25 patients completed the first 4 rituximab infusions and the 6-month induction phase and 24 patients completed ≥18 months of follow up. Infusion-related reactions were the most common adverse effect (AE), occurring in 32% of patients with the first infusion and were less frequent thereafter, according to the study. Sixty-eight percent of patients acquired infections and 10 serious AEs occurred in 7 patients during the 6-month remission induction phase. Over the course of the study, 27 serious AEs were reported in 12 patients but no deaths were reported.
 
According to the exploratory efficacy assessment, 56% of patients achieved remission by month 6 and 100% achieved remission by month 18. Overall, the median duration of remission during the study was 56 weeks.
 
Rituximab is currently indicated for 4 autoimmune diseases: GPA, MPA, pemphigus vulgaris, and rheumatoid arthritis.
 
“We are committed to delivering new treatment options for rare diseases, such as pediatric GPA and MPA, for which there are currently no approved medicines,” Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech, said in a statement. “We will continue to work closely with the FDA to bring Rituxan to children with these 2 serious and potentially life-threatening diseases.”
 
References
 
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children With Two Rare Blood Vessel Disorders [news release]. Genentech. https://www.gene.com/media/press-releases/14797/2019-06-11/fda-grants-priority-review-to-genentechs. Accessed June 12, 2019.
 
Brogan P, Cleary G, Hersh AO, et al. Pediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$